clinical trial · NCT03240809
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
Bausch Health Americas, Inc.·phase4·active not recruiting·n = 2
PsoriasisBrodalumabBrodalumab
brief summary
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
started
Jan 24, 2020
primary completion
Dec 1, 2028
completion
Jun 1, 2029
last updated
Sep 16, 2025
detailed description
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects (6 to \< 18 Years Old) With Severe Plaque Psoriasis
official title
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects (6 to < 18 Years Old) With Severe Plaque Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol